Rise of Drug‑Resistant Fungal Pathogen Candida auris in India – Insights from PGIMER Research

Overview Fungal infections that were once limited to skin problems are now emerging as serious, sometimes fatal, threats. The most alarming development is the spread of Candida auris in India. Research by the Postgraduate Institute of Medical Education and Research ( PGIMER ) reveals how the pathogen evades existing antifungal drugs. Key Developments More than 90% of clinical isolates of C. auris are resistant to azole drugs such as fluconazole. About 30% show resistance to polyenes, while most remain susceptible only to echinocandins . Genomic studies identified extra copies of the Erg11 gene and mutations in the Fks1 gene. High doses of echinocandins trigger the Eagle effect , limiting the usefulness of standard susceptibility tests. Important Facts Fungi thrive below 30 °C, but global warming creates a selective pressure for heat‑tolerant strains that can survive at the human body temperature of 37 °C. This “ mammalian selection hypothesis ” explains the recent surge in invasive fungal diseases. In Indian hospitals, roughly 20% of reported infections are fungal, yet many lack diagnostic capacity. PGIMER’s repository of 15,000 clinical isolates aids nationwide identification and research. UPSC Relevance Understanding emerging fungal threats touches upon several GS papers: GS3 – Health and Disease Management: drug‑resistant infections, antimicrobial stewardship, and impact on public health. GS3 – Environment: link between climate change and pathogen evolution. GS1 – Institutions: role of research bodies like PGIMER in disease surveillance. GS4 – Ethics: equitable access to advanced diagnostics and newer antifungals. Way Forward Policy makers should consider: Strengthening laboratory infrastructure in hospitals for accurate fungal identification. Updating susceptibility‑testing guidelines to include higher drug concentrations, especially for echinocandins . Promoting research on combination therapies that block compensatory pathways, reducing reliance on a single drug class. Investing in climate‑adaptation strategies to monitor heat‑tolerant pathogens. Only a coordinated effort between clinicians, researchers, and policymakers can curb the rise of drug‑resistant fungi and safeguard public health.